Start free trial
Trending New Genres Authors
EnglishEnglish
EspañolSpanish
简体中文Chinese
繁體中文Chinese (Traditional)
FrançaisFrench
DeutschGerman
日本語Japanese
PortuguêsPortuguese
ItalianoItalian
한국어Korean
РусскийRussian
NederlandsDutch
العربيةArabic
PolskiPolish
हिन्दीHindi
Tiếng ViệtVietnamese
SvenskaSwedish
ΕλληνικάGreek
TürkçeTurkish
ไทยThai
ČeštinaCzech
RomânăRomanian
MagyarHungarian
УкраїнськаUkrainian
IndonesiaIndonesian
DanskDanish
SuomiFinnish
БългарскиBulgarian
עבריתHebrew
NorskNorwegian
HrvatskiCroatian
CatalàCatalan
SlovenčinaSlovak
LietuviųLithuanian
SlovenščinaSlovenian
СрпскиSerbian
EestiEstonian
LatviešuLatvian
فارسیPersian
മലയാളംMalayalam
தமிழ்Tamil
اردوUrdu
Searching...
SoBrief
The Cholesterol Myths

The Cholesterol Myths

Exposing the Fallacy That Saturated Fat and Cholesterol Cause Heart Disease
A cholesterol number predicts risk, but does it cause heart disease? The evidence is less simple.
by Uffe Ravnskov 2000 297 pages
4.29
184 ratings
Listen
Immersive
V2.3
Amazon Kindle Audible
Try Full Access for 3 Days
Unlock listening & more!
Continue

Key Takeaways

Ravnskov disputes the diet-heart chain, from saturated fat to infarction.

A warning unsettles Karla. The book opens with Karla, a healthy 62-year-old who is told that her cholesterol puts her at risk of a heart attack. She becomes anxious, changes the food she enjoys, and feels worse. Her story shows the human cost of medical advice delivered as a prediction rather than a probability. It introduces Ravnskov’s central challenge: that saturated fat raises blood cholesterol, cholesterol causes artery disease, and artery disease causes heart attacks is a chain of claims, not one self-evident fact.

The book disputes each link. Ravnskov argues that contradictory studies and weak measurements undermine the chain, and that lowering cholesterol is not a reliable way to prevent heart disease. This is the book’s thesis, not today’s medical consensus. Its case is best read as a challenge to overconfident claims, not as a guide to stopping prescribed treatment.

Analysis

What's striking is how a risk message can change a person's health experience before it changes any biological risk. Karla's distress illustrates why clinicians should communicate absolute probabilities, uncertainty, and options rather than turn a lab value into a countdown. The book is right to scrutinize confident public messaging. But its broad conclusion does not reflect current evidence: genetic, biological, and clinical research supports a causal role for LDL particles in cardiovascular disease, and LDL-lowering treatments reduce events. A compelling story can reveal harms of communication, but it cannot settle the biology.

Treat national correlations as clues, not proof of dietary causation.

A striking plot has limits. Ancel Keys compared dietary fat and heart-disease deaths across six countries, producing a persuasive-looking pattern. Ravnskov notes that data were available from 22 countries, and that including more of them weakened the association. He also questions the underlying measures: food available in a country is not the same as food people eat, while death certificates can misidentify the cause of death.

Prosperity confounds the picture. In the same national comparisons, heart-disease deaths also tracked cigarette sales, cars, protein, and sugar. Ravnskov argues that wealth could connect these factors, through changes in lifestyle, exposure, diagnosis, and life expectancy. A correlation between fat and recorded deaths, he says, cannot by itself establish that fat caused the deaths.

Analysis

This is a useful lesson in ecological inference: a pattern across countries cannot automatically describe what happens to individuals, much less identify a cause. The book's examples make confounding intuitive. If several features rise together with prosperity, assigning the outcome to one food requires more than a tidy graph. Still, a weak or messy country-level correlation does not disprove a causal effect. National comparisons have limited resolution, and their imperfections call for stronger study designs, not a verdict in either direction.

Use regional and cultural exceptions to ask what averages hide.

Look beyond the national average. In the Seven Countries Study, Ravnskov contrasts Finnish districts where heart attacks differed roughly fivefold despite only small differences in cholesterol and diet. He treats this mismatch as a clue that other influences deserve attention. The study’s headline comparisons between countries, he argues, can obscure important differences within them.

The Kenyan herders complicate the story. The Masai and Samburu traditionally consumed large amounts of milk, meat, or blood, yet researchers measured low blood cholesterol among them. Autopsies described atherosclerotic changes, but the severe raised plaques associated with obstructed arteries were uncommon in the Masai samples, and the investigators found no signs of prior heart attacks in the hearts examined. Ravnskov points to physical activity and other lifestyle differences as possible explanations.

Analysis

The most valuable move here is not treating an outlier as an inconvenient footnote. Regional variation can generate better questions about activity, social conditions, and local exposures. But an exception is not a controlled experiment. Differences between communities may reflect many factors at once, and a small autopsy sample cannot establish what protects a whole population. The Masai example challenges a simple dietary story; it does not show that diet is irrelevant or that one group’s experience can be transferred directly to another.

A risk marker can forecast danger without being the cause.

Prediction is not explanation. The book distinguishes a risk factor, a feature associated with a higher chance of disease, from a cause that produces it. Age, smoking, weight, blood pressure, and stress can affect heart risk while also influencing cholesterol. In that case, cholesterol might partly mark other processes rather than act as the sole culprit.

Percentages can distort intuition. Ravnskov revisits a study of more than 300,000 men: the highest cholesterol group had about 1.3% die from a heart attack over six years, compared with about 0.3% in the lowest group. The relative difference sounds enormous, while the absolute difference is about one percentage point. He also cites inconsistent findings across age groups, sexes, and populations to argue that cholesterol’s predictive value is not uniform.

Analysis

The distinction between prediction and causation is foundational in epidemiology. A marker can still be clinically useful even when it is not the mechanism, and a causal factor can have modest predictive power for an individual because risk depends on many variables. The absolute-risk example is a strong communication lesson: relative percentages need a denominator. Yet differences across groups do not alone negate causality. Effects can vary by age, baseline risk, and other biology, so subgroup patterns require careful analysis rather than blanket conclusions.

Judge dietary advice by patient outcomes, not cholesterol changes alone.

A laboratory shift is not a health outcome. Ravnskov argues that diets can sometimes lower measured cholesterol modestly, but that this does not prove they prevent heart attacks. He reviews trials in which people were asked to change food, smoking, weight, or exercise, making it difficult to isolate the contribution of diet. In the North Karelia project, heart deaths fell in the intervention region, but they also fell elsewhere in Finland, complicating claims that the campaign caused the decline.

The trial results were mixed. In one soybean-oil trial among people who had already had heart attacks, the book reports 15 heart-attack deaths in the intervention group and 14 in the comparison group. Another trial reported fewer heart deaths but more cancer deaths. Ravnskov uses these mixed findings to question whether dietary cholesterol reduction improved overall survival.

Analysis

This section correctly warns against treating a change in a blood test as proof of a better life or longer survival. It also shows why multi-part public-health campaigns cannot identify which component produced an outcome. But the book's selected trials do not represent the full body of nutrition research, and null findings in older studies do not settle current questions. Dietary effects depend on what replaces what, the population studied, and the outcome measured. Good evaluation needs a broad evidence base, not a single biomarker or a handful of trials.

A drug's success does not prove its presumed mechanism.

Statins raise a mechanism question. Ravnskov reviews trials in which statins reduced cardiovascular events, including the Scandinavian 4S trial in people with prior heart attacks. He argues that benefit did not consistently track the amount of cholesterol reduction, and that some benefits appeared in groups for whom cholesterol was not a strong predictor. From this, he proposes that statins may act through other biological effects, including effects on inflammation, blood vessels, and clotting.

That argument has limits. A drug can have several effects at once, so a trial showing that it works does not by itself reveal which effect matters most. Conversely, a weak relationship between individual cholesterol change and outcome does not prove that cholesterol has no causal role. The book uses this uncertainty to challenge the cholesterol hypothesis; current evidence supports LDL lowering as an important part of statin benefit.

Analysis

Separating a treatment's effect from its proposed mechanism is sound scientific practice. Pharmacology often reveals that drugs do more than their original designers expected, and identifying those pathways can improve treatment. The challenge is to avoid a false choice: a statin can affect inflammation and still reduce risk partly by lowering LDL. Individual response data are noisy, and exposure-response tests have limitations. Mechanistic uncertainty is a reason to investigate mediation, not a reason to dismiss a treatment target supported by multiple lines of evidence.

Compare absolute benefits with burdens before treating healthy people.

Small benefits need clear denominators. The book contrasts the relative-risk headlines used in statin trials with absolute differences. In 4S, for example, Ravnskov reports fatal heart attacks in about 8.5% of the control group and 5% of the treatment group over roughly five years. In the AFCAPS/TexCAPS primary-prevention trial, he reports a much smaller difference in fatal heart attacks, about 0.45% versus 0.33%.

Harms must be assessed too. Ravnskov argues that trial selection and reporting may have undercounted side effects, and raises concerns about muscle problems, memory, mood, and cancer. These claims vary in evidential strength and should not be treated as established conclusions. The practical lesson is to weigh likely absolute benefit, possible harms, baseline risk, and patient priorities rather than treating a cholesterol number in isolation.

Analysis

The distinction between relative and absolute benefit is essential for informed consent. A relative reduction can sound dramatic while the number of people who benefit depends heavily on their starting risk. That makes the same treatment decision look different in someone with prior cardiovascular disease and someone with no known disease. The book is also right that harms deserve systematic measurement, not dismissal. Its specific claims about broad statin harms, however, go beyond what its cited anecdotes and selected trials can establish. Treatment decisions should use current evidence and individual risk, not this book alone.

Separate natural polyunsaturated fats from industrial trans fats.

The book questions a substitution. Ravnskov challenges advice to replace saturated fats with polyunsaturated oils. He argues that polyunsaturated fats are chemically more vulnerable to oxidation, and cites animal studies and other observations to raise concerns about excessive intake, immune function, and cancer. He also describes trans fats, produced when oils are partially hydrogenated, as chemically altered fats used in products such as baked goods and some margarines.

These are different claims. The book's concerns about high intakes of polyunsaturated oils rely heavily on animal experiments and do not establish harm from ordinary human diets. Its discussion of trans fats is a separate issue: it describes how industrial processing changes fats and raises questions about biological effects. The distinction matters because evidence about one kind of fat cannot automatically be applied to all vegetable oils.

Analysis

This is a useful reminder that broad labels such as vegetable oil can hide major differences in composition and processing. It also anticipates an important principle in nutrition: the health effect of a food often depends on its replacement and the overall dietary pattern. The book, however, gives oxidation mechanisms more weight than direct human outcome evidence warrants. Evidence on industrial trans fats should not be conflated with evidence on unsaturated fats, and theoretical chemical vulnerability alone cannot establish that a food causes disease.

Demand transparent evidence without turning skepticism into a rival dogma.

The book audits scientific authority. Ravnskov argues that researchers and public-health bodies sometimes highlighted supportive studies, minimized contradictory findings, and relied on reviews that repeated claims without returning to original data. He also points to financial ties among researchers, drug companies, food producers, and guideline panels as reasons to scrutinize conclusions. His account of the cholesterol campaign presents scientific consensus as something that can become self-reinforcing.

His closing demand is personal scrutiny. Readers should examine the methods, measures, and full results, not accept a conclusion because a prestigious committee endorses it. That is a strong standard for reading science. But the book’s own case also requires that standard: its critique sometimes treats selected counterexamples as decisive and gives less weight to evidence that supports the opposing view.

Analysis

Transparency, independent replication, and disclosure of financial ties strengthen science; they are not signs of hostility toward medicine. The book makes a valuable case for checking how claims travel from original studies into reviews and public guidance. Yet suspicion is not a substitute for causal evidence. Conflicts of interest can bias research, but their presence does not prove a conclusion false. Skepticism is most productive when applied symmetrically, to consensus claims and dissenting claims alike, with methods and total evidence carrying more weight than motives.

Analysis

The Cholesterol Myths is a polemical review of medical evidence, organized around Ravnskov’s effort to dismantle a causal chain linking saturated fat, blood cholesterol, atherosclerosis, and heart attacks. Its strongest contribution is methodological. It asks readers to notice when a striking correlation rests on national averages, when a relative-risk figure obscures a small absolute difference, when a biomarker is mistaken for a clinical outcome, and when a bundled intervention prevents attribution. Karla’s experience gives that critique a human cost: public-health messages can produce anxiety and unnecessary restriction when communicated as certainty.

The book’s weakness is that it applies scientific skepticism unevenly. It often treats a conflicting observation as fatal to a complex probabilistic hypothesis, while treating null results as proof of no effect. It emphasizes selected studies that support its case, criticizes selection in mainstream reviews, and at times relies on the same selective method. Claims about statins causing cancer, aggression, or cognitive decline are especially consequential, but the evidence presented does not establish those broad conclusions. The book also predates much subsequent research and should not be used as current treatment guidance.

Current cardiovascular science supports a causal role for LDL-containing particles, based on converging evidence from genetics, biological mechanisms, and randomized trials showing that LDL reduction lowers cardiovascular events. That does not make every dietary recommendation equally certain, nor does it mean every person has the same expected benefit from treatment. The value of this book is therefore less its verdict on cholesterol than its insistence that claims be tested against outcomes, transparent methods, and the full record of evidence. It is best read as a critique of scientific overconfidence, not as a reason to disregard medical advice or stop prescribed medication.

Summary in 30 Seconds
A risk marker can predict disease without causing it, and national correlations cannot establish that diet caused heart attacks. In a study of more than 300,000 men, heart-attack deaths over six years were about 1.3% in the highest cholesterol group and 0.3% in the lowest, a one-percentage-point absolute difference. Changes in cholesterol do not alone prove better health. The book questions diet advice and statin mechanisms, but its challenges are disputed: broader evidence supports LDL as a cause of cardiovascular disease and LDL reduction as beneficial.
Contains spoilers

Last updated:

Report Issue

Review Summary

4.29 out of 5
Average of 184 ratings from Goodreads and Amazon.

The Cholesterol Myths receives mostly positive reviews, with readers praising its clear explanations of common misconceptions about fat and cholesterol. Many appreciate the author's logical presentation of facts and evidence, finding it eye-opening and thought-provoking. Reviewers commend the book's organization into sections addressing specific myths. Some readers express concern about the medical establishment's stance on cholesterol and statins. A few note translation issues affecting readability. Overall, reviewers consider it an important, well-researched work challenging conventional wisdom about diet and heart disease.

Your rating:
4.64
135 ratings
Want to read the full book?

Glossary

diet-heart idea

diet-to-heart disease hypothesis

Ravnskov’s name for the proposed sequence in which dietary saturated fat and cholesterol raise blood cholesterol, elevated cholesterol promotes atherosclerosis, and atherosclerosis leads to coronary heart disease. The book disputes the strength and completeness of evidence for this sequence. The term describes the hypothesis under debate, not an established conclusion.

risk factor

associated predictor of risk

A characteristic associated with a greater or smaller chance of an outcome. Ravnskov emphasizes that an association does not by itself show that the characteristic causes the outcome. For example, a factor may track heart disease because it is connected to another cause, or because both are related to age, wealth, or lifestyle.

surrogate outcome

indirect treatment measure

A measurement used in place of a direct clinical outcome such as a heart attack, disability, or death. In the book, changes in blood cholesterol or coronary-artery diameter are treated as surrogate outcomes. Such changes may be informative, but they do not automatically prove that patients live longer or experience fewer serious events.

exposure-response

effect linked to exposure change

A relationship between the amount of exposure to a treatment or factor and the resulting outcome. Ravnskov argues that if lowering cholesterol is the mechanism behind statin benefits, people whose cholesterol falls more should generally gain more protection. The book regards the inconsistent relationships reported in some trials as a challenge to that mechanism.

pleiotropic effects

multiple effects from one drug

Effects of a drug beyond the action for which it is best known or prescribed. Ravnskov uses the term for statin actions that may involve inflammation, blood-vessel cells, or clotting as well as cholesterol production. The term allows for several mechanisms, but does not by itself show which mechanism produces a clinical benefit.

familial hypercholesterolemia

inherited high-cholesterol disorder

An inherited condition affecting the body’s handling of cholesterol, often producing very high blood-cholesterol levels. The book argues that people with this uncommon disorder should be distinguished from the wider population when interpreting studies. Their biology and cardiovascular risks cannot automatically establish what cholesterol levels mean for everyone else.

Multiple Risk Factor Intervention Trial (MR.FIT)

multi-factor prevention trial

A large American trial that assigned men considered at elevated heart-disease risk to an intensive program addressing cholesterol, smoking, and blood pressure, or to usual care. Because several risk factors were targeted at once, the trial could assess the program as a whole but could not isolate the effect of dietary change or cholesterol reduction alone.

Seven Countries Study

international heart-risk study

A long-running observational study comparing diet, blood measurements, and heart-disease outcomes in selected populations across seven countries. Ravnskov focuses on differences between populations and between regions within the same country, arguing that the reported patterns do not support a simple dietary explanation. Observational comparisons can reveal patterns but cannot alone establish causation.

About the Author

Uffe Ravnskov is a physician and independent researcher known for his controversial views on cholesterol and heart disease. He has extensively studied and criticized the lipid hypothesis, which suggests a causal link between high cholesterol levels and cardiovascular disease. Ravnskov's work challenges mainstream medical opinions and has garnered both support and criticism from the scientific community. He has authored several books on the subject, including "The Cholesterol Myths," which has been translated into multiple languages. Ravnskov's research focuses on re-evaluating the role of cholesterol in health and questioning the widespread use of cholesterol-lowering medications.

Download PDF

To save this The Cholesterol Myths summary for later, download the free PDF. You can print it out, or read offline at your convenience.
Download PDF
File size: 0.34 MB     Pages: 16

Download EPUB

To read this The Cholesterol Myths summary on your e-reader device or app, download the free EPUB. The .epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.
Download EPUB
File size: 1.43 MB     Pages: 19
Want to read the full book?
Follow
Listen
Home
Swipe
Library
Get App
Try Full Access for 3 Days
Listen, bookmark, and more
Compare Features Free Pro
📖 Read Summaries
Read unlimited summaries. Free users get 3 per month
🎧 Listen to Summaries
Listen to unlimited summaries in 40 languages
—
❤️ Unlimited Bookmarks
Free users are limited to 4
—
📜 Unlimited History
Free users are limited to 4
—
📥 Unlimited Downloads
Free users are limited to 1
—
Risk-Free Timeline
Today: Get Instant Access
Listen to full summaries of 26,000+ books. That's 12,000+ hours of audio!
Day 2: Trial Reminder
We'll send you a notification that your trial is ending soon.
Day 3: Your subscription begins
You'll be charged on Nov 25,
cancel anytime before.
Consume 2.8× More Books
2.8× more books Listening Reading
Our users love us
1M+ readers
Trustpilot Rating
TrustPilot
4.6 Excellent
This site is a total game-changer. I've been flying through book summaries like never before. Highly, highly recommend.
— Dave G
Worth my money and time, and really well made. I've never seen this quality of summaries on other websites. Very helpful!
— Em
Highly recommended!! Fantastic service. Perfect for those that want a little more than a teaser but not all the intricate details of a full audio book.
— Greg M
Save 62%
Yearly
$119.88 $44.99/year/yr
$3.75/mo
Monthly
$9.99/mo
Start a 3-Day Free Trial
3 days free, then $44.99/year. Cancel anytime.
Unlock a world of fiction & nonfiction books
26,000+ books for the price of 2 books
Read any book in 10 minutes
Discover new books like Tinder
Request any book if it's not summarized
Read more books than anyone you know
#1 app for book lovers
Lifelike & immersive summaries
30-day money-back guarantee
Download summaries in EPUBs or PDFs
Cancel anytime in a few clicks

Why one summary?

Scanner
Find a barcode to scan

⭐
⭐
⭐
We have a special gift for you
Open
38% off
DISCOUNT FOR YOU
⭐
⭐
⭐
$79.99
$49.99/year
Only $4.16 per month
Continue
2 taps to start, super easy to cancel
Settings
General
Widget
Loading...